Antonio Jimenez Jimenez MD MS; ASH 2025: Donor Choice No Longer a Barrier to Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 2AM EDT 5 min · 24 Sep 2026 · NPR News Now

Entertainment Catch-Up: Presley Gerber, Phones in Theatres and Channing Tatum's Troll Account(?) 39 min · 24 Sep 2026 · Catch Up with Louise McSharry

2AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

How To Naturally Lift & Sculpt Your Face, Define Your Jawline & Age Better Without Injectables 1h 3m · 24 Sep 2026 · The Bossticks

Cómo dejar ir a alguien que todavía amas | Jueves de Lety & Ash | Episodio 697 22 min · 24 Sep 2026 · Se Regalan Dudas

Dead Internet 2026: DARPA, Peter Thiel, Alien AI & Memetic Magick 1h 47m · 24 Sep 2026 · Occult Symbolism and Pop Culture with Isaac Weishaupt

Report any issue

Source

Recorded19 Jan 2026

Publisheraudiomedica.com ↗

Handlerec:19315690

Show notes

Antonio Jimenez Jimenez MD MS, from the University of Miami, presented findings at ASH 2025 indicating that donor choice is less of a barrier to allogeneic stem cell transplantation for patients with hematologic malignancies. The National Marrow Donor Program Access Trial found that post-transplant cyclophosphamide enables a wider, more ethnically diverse range of patients to safely receive transplants from unrelated donors.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in